Back to Search
ETHAN CORCORAN, M.D., PH.D.
M.D., PH.D.
Pulmonary Disease Physician
NPI: 1841417532IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
MD150309(OR)
CMS Specialties
PrimaryCRITICAL CARE (INTENSIVISTS)
Education
DUKE UNIVERSITY SCHOOL OF MEDICINE
Class of 2002
Research & Publications (16)
Proteomic analysis of calcium/calmodulin-dependent protein kinase I and IV in vitro substrates reveals distinct catalytic preferences.
PMID 12538590·J Biol Chem·2003
7-preclinical
Defining Ca2+/calmodulin-dependent protein kinase cascades in transcriptional regulation.
PMID 11096122·J Biol Chem·2001
6-review
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice.
PMID 19584274·Cancer Res·2009
7-preclinical
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
PMID 19528458·Anticancer Res·2009
7-preclinical
In vivo method for establishing synergy between antibodies to epidermal growth factor receptor and vascular endothelial growth factor receptor-2.
PMID 19252838·Methods Mol Biol·2009
7-preclinical
Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a neutropenic mouse thigh infection model.
PMID 17954697·Antimicrob Agents Chemother·2008
7-preclinical
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
PMID 17085673·Clin Cancer Res·2006
7-preclinical
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
PMID 16641428·Antimicrob Agents Chemother·2006
7-preclinical
Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
PMID 16609035·Clin Cancer Res·2006
4-observational
1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.
PMID 16246560·Bioorg Med Chem Lett·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Request Appointment
This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.
Contact & Hours
- Address
- 10180 SE SUNNYSIDE RD
CLACKAMAS, OR 97015 - Phone
- (503) 571-2727
Quick Facts
- NPI
- 1841417532
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 24
- Publications
- 16
Are you this provider?
Claim Your Profile